It's won Government funding to evaluate the Paige system, which can identify areas of suspicious tissue.
The Paige Prostate Cancer Detection System also measures and grades the severity of tumours it detects.
Oxford University and partners - including Oxford University Hospitals - have won government funding to evaluate the system, which could help pathologists quickly identify suspicious areas of tissue.
It could then be used to influence important treatment decisions for patients, with hopes the software will soon become widely used in the NHS.
The study is happening, thanks to a successful NHSx Artificial Intelligence Health and Care Award application.
Professor Clare Verrill from Oxford University's Nuffield Department of Surgical Sciences and Oxford University Hospitals, said, 'I see this both as a natural evolution and key transformational point for histopathology. With this award we can advance the adoption of powerful technology to help pathologists by demonstrating the system-wide potential of using AI-based diagnostic systems in routine reporting.'
Oxford University is working with OUH, North Bristol NHS Trust and University Hospitals Coventry and Warwickshire - who will use Paige Prostate prospectively in a real-world cancer laboratory setting.
In all, the government is making £140 million available over four years to accelerate the testing and evaluation of artificial intelligence technologies.
Dr Margaret Horton, Business Lead for Europe at Paige and a co-Investigator on the project said, 'The NHSx program provides the ideal catalyst for the system-wide adoption of artificial intelligence-based technologies such as Paige Prostate to improve efficiency, accuracy and patient and staff experiences.
'The pathologists and principal investigators in this study are global leaders in the implementation of digital pathology and utilising innovation to advance diagnostic service delivery.'